retatrutide clinical trial results 2024 Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 for treatment of type 2 diabetes ESC 2024: Retatrutide improves lipid

US$ 29.25

★★★★★ 4.0 (10 reviews)

US$ 24.01

★★★★★ 4.3 (17 reviews)

US$ 25.04

★★★★★ 4.0 (28 reviews)

US$ 24.28

★★★★★ 4.4 (6 reviews)

US$ 24.83

★★★★★ 5.0 (13 reviews)

US$ 27.55

★★★★★ 4.1 (9 reviews)

US$ 25.38

★★★★★ 4.3 (27 reviews)

US$ 29.12

★★★★★ 5.0 (14 reviews)

US$ 20.49

★★★★★ 4.9 (16 reviews)

US$ 25.35

★★★★★ 4.6 (17 reviews)

US$ 27.59

★★★★★ 4.9 (20 reviews)

US$ 25.50

★★★★★ 5.0 (10 reviews)

US$ 28.79

★★★★★ 4.1 (13 reviews)

US$ 21.59

★★★★★ 4.8 (14 reviews)

US$ 22.86

★★★★★ 4.6 (23 reviews)

US$ 26.29

★★★★★ 4.4 (29 reviews)

US$ 28.81

★★★★★ 4.4 (27 reviews)

US$ 20.87

★★★★★ 4.1 (11 reviews)

US$ 27.11

★★★★★ 4.0 (14 reviews)

US$ 20.13

★★★★★ 4.2 (7 reviews)